Leerink Partnrs Issues Optimistic Forecast for NAMS Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Equities researchers at Leerink Partnrs upped their FY2028 earnings per share estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings of $0.44 per share for the year, up from their previous estimate of $0.39. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($2.06) per share.

A number of other analysts have also commented on NAMS. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday. Piper Sandler reissued an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $33.80.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $22.64 on Friday. The stock has a 50-day moving average of $17.51 and a 200-day moving average of $18.49. NewAmsterdam Pharma has a 1-year low of $8.64 and a 1-year high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, November 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.30. The business had revenue of $29.11 million for the quarter, compared to analyst estimates of $5.35 million.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. Artal Group S.A. purchased a new position in NewAmsterdam Pharma in the 1st quarter valued at approximately $18,920,000. Janus Henderson Group PLC acquired a new position in shares of NewAmsterdam Pharma during the first quarter worth about $15,018,000. Decheng Capital LLC acquired a new position in shares of NewAmsterdam Pharma during the second quarter worth about $7,684,000. TimesSquare Capital Management LLC purchased a new stake in NewAmsterdam Pharma during the first quarter worth about $5,407,000. Finally, Millennium Management LLC boosted its holdings in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after buying an additional 217,902 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.